Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 1.25B |
| Revenue (ttm) | 191.87M |
| Net Income (ttm) | -72.81M |
| Shares Out | 67.38M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | 8.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 949,443 |
| Open | 18.23 |
| Previous Close | 18.08 |
| Day's Range | 18.04 - 18.51 |
| 52-Week Range | 18.03 - 41.93 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 50.50 (+173.27%) |
| Earnings Date | Nov 9, 2023 |
About AMLX
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is h... [Read more]
Financial Performance
In 2022, AMLX's revenue was $22.23 million, an increase of 7700.00% compared to the previous year's $285,000. Losses were -$198.38 million, 125.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price forecast is $50.5, which is an increase of 173.27% from the latest price.
News
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate at two upcoming investor conferences on September 11-12.
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results.
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals announces it will report its second quarter 2023 financial results on Thursday, August 10, 2023.
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Webcast to Discuss the PSP Treatment Landscape and the Company's Clinical Development Plans on July 26, at 1:30pm ET.
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 - Will Seek Re-Examination.
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx signs LOI with the pCPA for ALBRIOZA™ and will now work with drug plans to ensure public coverage to eligible Canadians with ALS.
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023.
Amylyx says European drug regulator likely to reject ALS drug
Amylyx Pharmaceuticals Inc said on Tuesday the European drug regulator was likely to reject its amyotrophic lateral sclerosis (ALS) drug, sending its shares down 8.5% in premarket trading.
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union.
Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
The biotech sector is notoriously volatile, populated with plenty of unprofitable companies that soar on optimism about clinical trials. Those same stocks can later plummet on poor trial results, or a...
Final Trades: IBM, Exxon Mobil, Amylyx, and Home Depot
The final trades of the day with the Fast Money traders.
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results.
Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023.
Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX #APAC--Ms. Masako Nakamura joins Amylyx as a key leader with the goal of bringing AMX0035 to as many people who may benefit around the world as possible.
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX #NeurodegenerativeDiseases--Amylyx announces first participant dosed in exploratory open-label proof of biology study of AMX0035 in Wolfram syndrome (WS).
Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023.
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
CAMBRIDGE, Mass.
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2022 financial results on Monday, March 13, 2023...
Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX), today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the SVB Securities Global Biop...
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the completion of enrollment in PHOENIX, a global, 48-week, randomized, pla...
Amylyx Pharmaceuticals Announces Exclusive AMX0035 Distribution Agreement with Israel-Based Neopharm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced it has entered into an exclusive license and distribution agreement with Ne...
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual H...
Stocks moving after hours: Twitter, Amylyx Pharmaceuticals, AutoZone, Airbnb
Yahoo Finance Live's Seana Smith looks at several stocks trending in the after-hours trading session.
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the quarter ended September 30, 2022.
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
CAMBRIDGE, Mass.